These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 8540613)
1. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Vailancourt L; Ttu B; Fradet Y; Dupont A; Gomez J; Cusan L; Suburu ER; Diamond P; Candas B; Labrie F Am J Surg Pathol; 1996 Jan; 20(1):86-93. PubMed ID: 8540613 [TBL] [Abstract][Full Text] [Related]
2. The morphologic changes induced by hormone and radiation therapy on prostate carcinoma. Roznovanu SL; Rădulescu D; Novac C; Stolnicu S Rev Med Chir Soc Med Nat Iasi; 2005; 109(2):337-42. PubMed ID: 16607796 [TBL] [Abstract][Full Text] [Related]
3. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate]. Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant hormonal therapy: the Canadian experience. Labrie F; Cusan L; Gomez JL; Diamond P; Suburu R; Lemay M; Tetu B; Fradet Y; Bélanger A; Candas B Urology; 1997 Mar; 49(3A Suppl):56-64. PubMed ID: 9123738 [TBL] [Abstract][Full Text] [Related]
5. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial. Bullock MJ; Srigley JR; Klotz LH; Goldenberg SL Am J Surg Pathol; 2002 Nov; 26(11):1400-13. PubMed ID: 12409716 [TBL] [Abstract][Full Text] [Related]
6. Effects of neoadjuvant androgen deprivation therapy on prostatic cancer. Polito M; Muzzonigro G; Minardi D; Montironi R Eur Urol; 1996; 30 Suppl 1():26-31; discussion 38-9. PubMed ID: 8977987 [TBL] [Abstract][Full Text] [Related]
7. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group. McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740 [TBL] [Abstract][Full Text] [Related]
9. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. Têtu B; Srigley JR; Boivin JC; Dupont A; Monfette G; Pinault S; Labrie F Am J Surg Pathol; 1991 Feb; 15(2):111-20. PubMed ID: 1989458 [TBL] [Abstract][Full Text] [Related]
10. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. Montironi R; Magi-Galluzzi C; Muzzonigro G; Prete E; Polito M; Fabris G J Clin Pathol; 1994 Oct; 47(10):906-13. PubMed ID: 7525657 [TBL] [Abstract][Full Text] [Related]
11. Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Civantos F; Marcial MA; Banks ER; Ho CK; Speights VO; Drew PA; Murphy WM; Soloway MS Cancer; 1995 Apr; 75(7):1634-41. PubMed ID: 8826921 [TBL] [Abstract][Full Text] [Related]
12. Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Van der Kwast TH; Têtu B; Fradet Y; Dupont A; Gomez J; Cusan L; Diamond P; Labrie F Prostate; 1996 Apr; 28(4):227-31. PubMed ID: 8602398 [TBL] [Abstract][Full Text] [Related]
13. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Labrie F; Dupont A; Cusan L; Gomez J; Diamond P; Koutsilieris M; Suburu R; Fradet Y; Lemay M; Têtu B Clin Invest Med; 1993 Dec; 16(6):499-509. PubMed ID: 8013155 [TBL] [Abstract][Full Text] [Related]
14. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Witjes WP; Schulman CC; Debruyne FM Urology; 1997 Mar; 49(3A Suppl):65-9. PubMed ID: 9123739 [TBL] [Abstract][Full Text] [Related]
15. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838 [TBL] [Abstract][Full Text] [Related]